DEFA14A: Alcon to Acquire LENSAR in Deal Valued Up to $430 Million

Alcon is set to acquire LENSAR, enhancing its cataract equipment portfolio with advanced laser technology.

Summary

• Alcon plans to acquire LENSAR, a medical technology company specializing in advanced laser solutions for cataract treatment.
• The acquisition includes the ALLY Robotic Cataract Laser Treatment System and LENSAR's Streamline software.
• Alcon will purchase all outstanding LENSAR shares for $14.00 per share in cash, totaling approximately $356 million.
• A contingent value right (CVR) of up to $2.75 per share in cash is included, dependent on achieving 614,000 cumulative procedures with LENSAR's products between January 1, 2026, and December 31, 2027.
• The total potential consideration is up to approximately $430 million, representing a premium over LENSAR's recent trading prices.
• The transaction is expected to close in mid-to-late 2025, pending regulatory and stockholder approvals.
• North Run Capital affiliates, owning approximately 45.8% of LENSAR's voting stock, have agreed to support the merger.

Sentiment

Score: 8

Explanation: The document presents a positive outlook on the acquisition, highlighting the strategic benefits for both companies and the potential for future growth. The inclusion of a contingent value right also suggests confidence in LENSAR's ability to achieve its milestones.

Positives

• Alcon gains access to LENSAR's advanced laser technology, enhancing its cataract surgery offerings.
• LENSAR stockholders receive a significant premium over recent trading prices.
• The acquisition could expand the global reach of LENSAR's technology through Alcon's established distribution network.
• North Run Capital's support increases the likelihood of stockholder approval.

Negatives

• The contingent value right is subject to LENSAR achieving a specific milestone, creating uncertainty for stockholders.
• The transaction is subject to regulatory and stockholder approvals, which could delay or prevent the deal from closing.
• LENSAR may be required to pay a termination fee of $8,500,000 under certain circumstances.

Risks

• The merger may not be completed in a timely manner or at all due to regulatory or stockholder disapproval.
• Competing offers for LENSAR could emerge.
• The anticipated benefits of the merger may not be realized.
• Liabilities related to the merger may be unknown or underestimated.
• Legal proceedings may be instituted against LENSAR following the announcement of the merger.
• LENSAR's stock price may decline significantly if the merger is not consummated.

Future Outlook

The acquisition is expected to close in mid-to-late 2025, subject to customary closing conditions, including regulatory and stockholder approvals. Alcon aims to expand the global reach of LENSAR's technology and improve efficiency in cataract surgery.

Management Comments

• David Endicott, CEO of Alcon, stated that the acquisition will bring LENSAR's unique technologies into Alcon's equipment portfolio and expand the benefits of femtosecond laser technology globally.
• Nick Curtis, CEO of LENSAR, expressed excitement about Alcon's potential to advance next-generation laser technology for refractive cataract surgery.

Industry Context

The acquisition reflects a trend of consolidation in the medical technology industry, with larger companies acquiring innovative smaller firms to expand their product portfolios and market reach. The cataract surgery market is substantial, with millions of procedures performed annually, creating a significant opportunity for Alcon to leverage LENSAR's technology.

Comparison to Industry Standards

• The acquisition of LENSAR by Alcon is comparable to other acquisitions in the medical device industry, such as Johnson & Johnson's acquisition of Abbott Medical Optics, which also aimed to strengthen their position in the ophthalmology market.
• The contingent value right structure is a common mechanism used in acquisitions to share risk and reward between the acquirer and the target company's stockholders, aligning incentives for achieving specific milestones.
• The premium offered by Alcon is within the typical range for acquisitions of publicly traded medical technology companies, reflecting the value of LENSAR's technology and market position.

Stakeholder Impact

• LENSAR stockholders are expected to receive a premium for their shares.
• Alcon employees may benefit from the integration of LENSAR's technology into Alcon's product portfolio.
• Cataract surgeons may gain access to advanced laser technology through Alcon's expanded offerings.
• Cataract patients may benefit from improved surgical outcomes and efficiency.

Next Steps

• LENSAR will file a proxy statement with the SEC to solicit stockholder approval of the merger.
• The companies will seek regulatory approvals for the transaction.
• A special stockholder meeting will be announced soon to obtain stockholder approval in connection with the proposed merger.

Key Dates

Keywords

LENSAR, Alcon, acquisition, merger, cataract surgery, ALLY Robotic Cataract Laser Treatment System, contingent value right, North Run Capital, regulatory approval, stockholder approval